The number of cards turned over, an index of risk taking in the CCT, served as the primary dependent measure. Descriptive statistics for the number of cards turned over, calculated separately for each group and experimental condition, are provided in the Online Supplementary Material. We analyzed these data with a mixed ANOVA, with group (vmPFC patients, control patients, healthy controls) as a between-subjects factor and version (hot, cold), loss probability (1, 2, or 3 loss cards), gain amount (10, 20, or 30 points), and loss amount (250, 500, or 750 points) as within-subjects factors. Significant main effects and interactions were followed up with Bonferroni-corrected post hoc tests. In light of the small sample size in both patient groups, we additionally report non-parametric post hoc tests to follow up significant ANOVA effects that involved the group factor.
For ease of interpretation, we break down the ANOVA results into two sets. We first report the effects characterizing group and version effects on the number of cards turned over, regardless of the task parameters that varied from trial to trial (gain amount, loss amount, and loss probability). These effects provide a picture of overall risk appetite (Studer et al., 2015). Next we report the effects of information use (Figner et al., 2009), that is, sensitivity to trial-level variations in gain amount, loss amount, and loss probability. We tested only the main effects of these within-subjects factors, as well as their interactions involving the group factor, since these were the only effects relevant to the current research questions.
Risk appetite
The main effect of group on risk taking was significant, F(2, 39) = 6.02, p < .01, ηp2 = .24, as was the main effect of version, F(1, 39) = 29.86, p < .01, ηp2 = .43, and the Group × Version interaction, F(2, 39) = 15.90, p < .01, ηp2 = .45. Bonferroni follow-up comparisons revealed that healthy controls and patient controls did not differ significantly from each other, p = .19, but vmPFC patients differed significantly from each of the other groups, p < .01, showing increased risk taking (i.e., turning over more cards). A second set of Bonferroni follow-up tests examined version effects (hot vs. cold) on risk taking within each participant group. There was no significant effect for patient controls, p = .23 or for healthy controls, p = .13. For vmPFC patients, however, the version effect was significant, p < .01: VmPFC patients turned over more than twice as many cards in the hot version than in the cold version. These results are illustrated in Fig. 3 (top panel).
Given the small sample sizes in the patient groups, we sought to corroborate the results of the post hoc comparisons with nonparametric tests. A Kruskal-Wallis test yielded no significant group effect in the cold version, χ2(2) = 2.34, p = .31, but a significant effect of group emerged in the hot version, χ2(2) = 13.03, p < .01. Pairwise follow-up comparisons using the Mann-Whitney procedure for independent samples revealed that healthy controls and patient controls did not differ significantly from each other, U = 49, z = 1.74, p = .08. However, vmPFC patients differed significantly from healthy controls, U = 15.00, z = 3.18, p < .01, and from patient controls, U = 2.00, z = 2.56, p = .01, showing increased risk taking (i.e., turning over more cards). A second set of nonparametric post hoc tests, using the Wilcoxon signed-rank procedure for related samples, examined version effects (hot vs. cold) on risk taking within each participant group. There was no significant effect for healthy controls, z = 1.21, p = .23, or for patient controls, z = 1.15, p = .25. For vmPFC patients, however, the version effect was significant, z = 2.20, p = .03. Overall, the nonparametric tests confirmed the results of the parametric tests.
Risk adjustment
Gain amount had no significant effect on risk taking, F(2, 78) = .41, p = .69, ηp2 = .01, and there was no significant Group × Gain Amount interaction, F(4, 78) = 1.66, p = .17, ηp2 = .08. Loss amount had a significant effect, F(2, 78) = 10.86, p < .01, ηp2 = .22. Further analysis of this effect revealed a significant linear effect of loss amount on risk taking, F(1, 39) = 13.98, p < .01, ηp2 = .26, such that larger loss amounts led to reduced risk taking. There was no significant quadratic effect of loss amount, F(1, 39) = .05, p = .01, ηp2 < .01, and the Group × Loss Amount interaction was not significant, F(4, 78) = 1.69, p = .16, ηp2 = .08. The main effect of loss probability was also significant, F(2, 78) = 87.77, p < .01, ηp2 = .69. It was further qualified by a Group × Loss Probability interaction, F(4, 78) = 5.62, p < .01, ηp2 = .22, and by a Group × Version × Loss Probability interaction, F(4, 39) = 7.53, p < .01, ηp2 = .28.
To unpack the three-way interaction, we conducted follow-up ANOVAs separately for the hot and cold versions. In the hot version, there was a significant effect of loss probability, F(2, 78) = 65.92, p < .01, ηp2 = .63, but no significant Group × Loss Probability interaction, F(2, 78) = .43, p = .43, ηp2 = .05. In the cold version, there was a significant effect of loss probability, F(2, 78) = 46.80, p < .01, ηp2 = .55, and a significant Group × Loss Probability Interaction, F(4, 78) = 10.47, p < .01, ηp2 = .35. Healthy controls and patient controls reduced their risk taking as the probability of losing increased, ps < .01, whereas vmPFC patients did not rely on loss probability to modulate their risk taking, p = .91. However, when testing for group effects at each level of loss probability, no significant differences emerged, although there was a marginal effect at the lowest risk level (one loss card), F(2, 39) = 3.03, p = .06, ηp2 = .13. When we followed up this marginal effect with Bonferroni comparisons, no significant pairwise differences among the groups emerged, p > .18. The interaction of group, version, and loss probability is illustrated in Fig. 3 (bottom panels).
Again we also followed up the significant Group × Loss Probability interaction with nonparametric tests. Using a series of Friedman tests on mean ranks to capture effects of loss probability within each group, we found that control participants reduced their risk taking as the probability of losing increased (healthy controls: χ2[2] = 52.27, p < .01; patient controls: χ2[2] = 10.33, p < .01), whereas vmPFC patients did not rely on loss probability to modulate their risk taking, χ2(2) = .09, p = .96. However, when testing for group effects at each level of loss probability using Kruskal-Wallis tests, no significant differences emerged, χ2(2) ≤ 5.43, p ≥ 0.07. The results of the nonparametric tests thus aligned with those of the parametric tests.
Could the order of administration of the hot and cold CCT, which was counterbalanced across participants, have affected risk taking? To examine this possibility, we re-ran the ANOVA with task order (cold CCT first vs. hot CCT first) included as a between-subjects factor. There was no significant main effect of task order, nor any significant two-way interactions with group or version, on the number of cards drawn, p > .05. These findings suggest that task order did not affect overall risk appetite. Task order also showed no significant interactions with loss amount or with loss probability. There was, however, a significant interaction of task order and gain amount, F(1.69, 72) = 5.34, p = .01, ηp2= .129. Follow-up ANOVAs, conducted separately within each task-order group, revealed no significant effects of gain amount, in either task-order group, p > .05. Overall, it does not appear that the pattern of results was influenced by the order in which participants encountered the hot and cold versions of the CCT.
Number of losses in the hot CCT
In light of the finding that the vmPFC group showed increased risk appetite in the hot version, we analyzed the number of losses experienced in the hot CCT, collapsing across the 54 experimental trials and 12 dummy trials. A Kruskal-Wallis test showed that there was a statistically significant group difference in the number of losses, χ2(2) = 11.20, p < 0.01. Pairwise follow-up comparisons using the Mann-Whitney procedure revealed that the number of losses experienced by healthy controls (M = 11.00; SD = 1.34) and by patient controls (M = 8.83; SD = 3.06) was not significantly different, U = 51.5, z = 1.74, p = .08. However, vmPFC patients (M = 18.50; SD = 8.69) experienced more losses than healthy controls, U = 26.00, z = 2.86, p < .01, and patient controls, U = 3.00, z = 2.42, p = .02. Thus, compared with both control groups, vmPFC patients showed greater risk appetite in the hot CCT despite more frequent loss feedback.
Final points score
Did the group differences in risk appetite affect task success as measured by the final points score? A Kruskal-Wallis test showed no statistically significant group difference in the final points score in the cold CCT, χ2(2) = 4.82, p = .09. However, a significant group effect was present in the hot CCT, χ2(2) = 9.65, p < .01, which we further probed with pairwise Mann-Whitney tests. Healthy controls (M = 11,297.67; SD = 4,547.14) and patient controls (M = 8,195.00; SD = 4,447.12) showed no significant difference, U = 52.50, z = 1.59, p = .11, but final point scores of vmPFC patients (M = 18,851.67; SD = 6,188.08) were significantly higher than those of healthy controls, U = 27.00, z = 2.67, p < .01, and patient controls, U = 4.00, z = 2.24, p = .03. Thus, vmPFC patients’ heightened risk appetite in the hot CCT resulted in a higher final points score, compared with both control groups.
Response time
A final follow-up question was whether group differences in risk appetite were associated with group differences in response time (RT). Such differences could shed light on the impulsivity with which participants made their selections. In the cold CCT, response time refers to the time between the onset of the choice array and the selection of a number field (e.g., “17”) via mouse click. Given the positive skew of RT distributions for self-paced responses, we submitted each participant’s median RT in the cold CCT to the analysis. A Kruskal-Wallis test on mean ranks for median RT was nonsignificant, χ2(2) = 4.76, p = .09. Across the groups, the mean median RT in the cold CCT was 5,801 ms (SD = 4,494ms).
In the hot CCT, separate RTs were recorded for each selection within a trial. Here, RT referred to the time elapsed since the onset of the choice array (for the first selection) or to the time elapsed since the previous selection (all subsequent selections). A Kruskal-Wallis test on mean ranks for median RT was significant, χ2(2) = 10.07, p < .01. Follow-up Mann-Whitney tests showed no significant difference between healthy controls (M = 1,276 ms; SD = 536 ms) and vmPFC patients (M = 948 ms, SD = 238 ms), U = 51.00, z = 1.66, p = .10. In contrast, patient controls (M = 1,832 ms; SD = 331 ms) differed from both vmPFC patients, U = 0.00, z = 2.88, p < .01, and healthy controls, U = 32.00, z = 2.46, p = .01. In summary, there was no evidence for RT differences between vmPFC patients and healthy controls, whereas patient controls responded more slowly than participants in both other groups.